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1. Introduction
Crohn’s disease and ulcerative colitis are the two main forms of inflammatory 
bowel disease (IBD). While ulcerative colitis mainly causes mucosal inflammation 
of the rectum and the colon, Crohn’s disease is characterized by transmural inflam-
mation of the gastrointestinal tract anywhere from the mouth to the anus and gran-
uloma formation in about 30% of cases. Crohn’s disease can also cause deep ulcers, 
penetrating ulcers, stricture, fistula, abscess, perforation, malabsorption and 
perianal disease. Although both forms of IBD can cause extra-intestinal manifesta-
tions and malignancy, Crohn’s disease is, in fact, a much more severe disease and 
patients’ sufferings can be relentless if the disease is not under control. The natural 
course of Crohn’s disease is chronic inflammation with relapse and remission. As it 
affects mostly young population in the 20s and 30s, their prime time of life is ham-
pered. So patients suffering from Crohn’s disease always want to avoid any relapse 
and be in long-term remission. The exact etiology of Crohn’s disease is unknown. 
Genetics, environmental factors (smoking, anxiety, depression, stress) and altered 
gut microbiota play important roles in disrupting the immune homeostasis that 
results in uncontrolled inflammation of the gut. A systematic review found that 
the prevalence of Crohn’s disease was 319 cases per 100,000 people and the annual 
incidence was 20.2 cases per100,000 persons-year in the United States [1]. It is more 
commonly seen in the white population in the Western world, but any person of any 
ethnicity can be affected. It is slightly more common in females than in males. The 
incidence and prevalence of Crohn’s disease have been increasing globally. Kochar 
et al. found that United States born Asians and Asian immigrants suffer from more 
perianal and ocular Crohn’s disease compared with white Americans [2].
There are various laboratory, imaging and endoscopic studies available to 
diagnose and assess the severity of Crohn’s disease. Crohn’s Disease Activity Index 
(CDAI) and Harvey-Bradshaw Index (HBI) are commonly used to assess the activity 
of the disease. Classically, Crohn’s disease is divided into mild, moderate and severe 
disease. There are various immunomodulatory [6-mercaptopurine (6-MP), aza-
thiopurine (AZA), methotrexate (MTX), and janus kinase (JAK) inhibitors] and 
biologic agents (anti-tumor necrosis factor, anti-integrin, IL-12/IL-23 inhibitors 
and biosimilars) available at the present time for induction of remission and main-
tenance of remission of Crohn’s disease. Mild Crohn’s disease is generally treated by 
a short course of budesonide followed by maintenance with 6-MP, AZA or MTX. 
Moderate to severe disease is treated with systemic corticosteroid followed by bio-
logic agents with or without immunomodulatory agents. Primary non-response and 
secondary loss of response to the biologic agents and immunomodulators are not 
uncommon. These unfavorable outcomes can be evaluated by therapeutic monitor-
ing of trough levels of drugs, measuring anti-drug antibodies (for anti-TNF agents) 
and metabolite levels (for thiopurines) so that appropriate management strategy 
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can be taken [3]. The goal of treatment is not only clinical and endoscopic remission 
but also mucosal healing. Although many patients are able to maintain long-term 
remission, the treatment options are not optimal considering their efficacy rate and 
side effect profile. As a result, many clinical trials are ongoing for better control of 
Crohn’s disease. Many biologic agents are in the pipeline to be released into the mar-
ket. Many patients ultimately need surgery when medical therapy fails and when 
complications occur. Fortunately, the surgery rate in Crohn’s disease is decreasing. 
A population-based time-trend analysis showed that the incidence rates for surgery 
in Crohn’s disease had been decreasing by about 8.4% each year from 1996 to 2013 
[4]. Unfortunately, surgical intervention is not curative and patients still need to 
be on immunosuppressive or biologic agents to prevent recurrence of the disease. 
Preventive care is an important aspect of management of Crohn’s disease. Because 
of immune dysregulation, patients are at increased risk of developing various viral 
and bacterial infections. They should be immunized against pneumococcus, menin-
gococcus, mumps, measles, rubella, diphtheria, tetanus and varicella zoster virus. 
They are also prone to develop osteopenia, osteoporosis and deficiency of iron, vita-
min and micronutrients. Baseline bone densitometry should be done, and calcium, 
vitamin D, iron, vitamin B12, folic acid and fat-soluble vitamins supplementation 
should be considered. Patients with Crohn’s disease are also at risk of developing of 
skin cancer (melanoma and non-melanoma). Thiopurines increase the chance of 
developing non-melanoma skin cancer and there is an increased risk of developing 
melanoma after using biologic agents (anti-TNF, anti-integrin). Patients should 
avoid sun exposure by using sunscreens and annual skin cancer surveillance should 
be done by the dermatologist. Patients with perianal Crohn’s disease are at increased 
risk of developing Human Papilloma Virus (HPV)-related anal canal squamous 
cell cancer and very rarely anal canal adenocarcinoma. They should receive HPV 
vaccination to reduce HPV-related malignancy. Female patients with Crohn’s disease 
on immunomodulators or biologic agents have increased risk of developing cervi-
cal high-grade dysplasia/cancer. They should have regular PAP smear to prevent 
cervical neoplasia. Female patients with Crohn’s disease in remission have the same 
chance of having conception, normal pregnancy and delivery as normal women 
without Crohn’s disease. Pregnancy can have beneficial effects on Crohn’s disease 
such as less symptoms during pregnancy, less future flare up and less need of future 
surgery. But if the disease is active, the chance of becoming pregnant is much less. 
Active disease during pregnancy can cause miscarriage, premature delivery and 
stillbirth. Thiopurines and anti-TNF agents are safe to be used throughout the 
pregnancy, and breastfeeding is also compatible with both agents. Methotrexate is 
teratogenic and cannot be used during pregnancy or lactation. In fact, both man 
and woman should stop taking MTX 3 months prior to planned pregnancy [5].
Taking care of mental health is another important part of management of 
Crohn’s disease. Patients may suffer from anxiety, depression and narcotic related 
problems. Various factors may contribute to psychiatric comorbidity which include 
pain, insomnia, psychosocial stress, frequent hospitalizations, surgical procedures, 
presence of ostomy, history of proctocolectomy, long duration of Crohn’s disease 
and history of traumatic childhood experiences [6]. During each outpatient visit, 
patients should be asked about their mental and emotional wellbeing, and appro-
priate referral to the psychologist or psychiatrist should be given.
In conclusion, Crohn’s disease is primarily an idiopathic chronic inflammatory 
bowel disease with the potential of involving multiple organs. Benign and malig-
nant complications as well as psychiatric comorbidity can occur. Management of 
Crohn’s disease may require multi-specialty team that include primary care physi-
cian, gastroenterologist, surgeon, dietitian, interventional radiologist, obstetrician, 
gynecologist, oncologist, dermatologist, psychiatrist and psychologist. Preventive 
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healthcare and mental healthcare are also very important part of management of 
Crohn’s disease. There are many support groups available in national organizations 
in individual countries such as Crohn’s and Colitis Foundation of America, National 
Association for Colitis and Crohn’s Disease in the United Kingdom, and Crohn’s and 
Colitis Australia. Patients with Crohn’s disease should join these support groups 
where they can communicate, find emotional supports, get answers to their ques-
tions and share their experiences with others living with the same disease.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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